- Home
- GRF vs CRVO Comparison
GRF vs CRVO Comparison
Compare GRF & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | CRVO |
|---|---|---|
| Founded | 1989 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 37.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | GRF | CRVO |
|---|---|---|
| Price | $10.09 | $3.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 2.1K | ★ 30.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.47 | $3.51 |
| 52 Week High | $11.85 | $13.13 |
Technical Indicators
Market Signals| Indicator | GRF | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 45.80 |
| Support Level | $9.96 | $3.55 |
| Resistance Level | $10.81 | $4.41 |
| Average True Range (ATR) | 0.14 | 0.29 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 46.11 | 42.67 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.